The effect of vardenafil on endothelial function of brachial and cavernous arteries

International Journal of Impotence Research

Volumn 18, Issue 5, 2006, Pages 464-469

  Mazo, E ^a   Gamidov, S ^a   Iremashvili, V ^a  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Brachial arteries; Cavernous arteries; Endothelial dysfunction; Erectile dysfunction; Flow mediated dilation; PDE 5 inhibitors

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PLACEBO; VARDENAFIL;

ADULT; AGED; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTERY OCCLUSION; ARTICLE; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS CAVERNOSUM; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERECTILE DYSFUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PENIS ARTERY; PRIORITY JOURNAL; ULTRASOUND;

ADULT; AGED; AGED, 80 AND OVER; BRACHIAL ARTERY; ENDOTHELIAL CELLS; ERECTILE DYSFUNCTION; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; MIDDLE AGED; PENIS; PIPERAZINES; SULFONES; TRIAZINES;

EID: 33748319486     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901454     Document Type: Article

References (21)

1. NIH Consensus Development Conference Statement. NIH consensus development panel on impotence. Int J Impot Res 1993; 4: 181-284.
2. Parazzini F, Menchini FF, Bortolotti A, Calabro A, Chatenoud L, Colli E et al. Frequency and determinants of erectile dysfunction in Italy. Eur Urol 2000; 37: 43-49.
3. Chew KK, Earle CM, Stuckey BG, Jamrozik K, Keogh EJ. Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int J Impot Res 2000; 12: 41-45.
4. Roumeguere T, Wespes E, Carpentier Y, Hoffmann P, Schulman CC. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003; 44: 355-359.
5. Martin-Morales A, Sanches-Cruz J, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the epidemiologia de la disfuncion erectil masculina study. J Urol 2001; 166: 569-574.
6. Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ. Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J Androl 2003; 24(Suppl 6): S17-S37.
7. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75: 191-236.
8. Francis SH, Corbin JD. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep 2003; 4: 457-465.
9. Virag R. Flow-dependent dilatation of the cavernous artery. A potential test of penile NO content. J Mal Vascul 2002; 27: 214-217.
10. Virag R, Floresco J, Richard C. Impairment of shear-stress-mediated vasodilation of cavernous arteries in erectile dysfunction. Int J Impot Res 2004; 16: 39-42.
11. Mazo E, Gamidov S, Andranovich S, Iremashvili V. Testing endothelial function of brachial and cavernous arteries in patients with erectile dysfunction. J Sex Med 2006 (in press; DOI:10.111/j.1743-6109.2005.00098.x).
12. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003; 108: 2054-2059.
13. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845-851.
14. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002; 25: 1336-1339.
15. Vlachopoulos C, Tsekoura D, Alexopoulos N, Panagiotakos D, Aznaouridis K, Stefanadis C. Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction. Am J Hypertens 2004; 17: 1040-1044.
16. Guazzi M, Tumminello G, Di Marco F, Guazzi MD. Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin Pharmacol Ther 2004; 76: 371-378.
17. Rosano GMC, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005; 47: 214-220.
18. Dishy V, Sofowora G, Harris PA, Kandcer M, Zhan F, Wood AJ et al. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clin Pharmacol Ther 2001; 70: 270-279.
19. Dishy V, Harris PA, Pierce R, Prasad HC, Sofowora G, Bonar HL et al. Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers. Br J Clin Pharmacol 2004; 57: 209-212.
20. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179-184.
21. Halcox JPJ, Nour KRA, Zalos G, Mincemoyer R, Waclawiw MA, Rivera CE et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40: 1232-1240.